A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
about
Aurora Kinase Inhibitors: Current Status and OutlookAurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A ReviewFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsOptimizing combination therapies with existing and future CML drugsInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsAurora kinases in head and neck cancerA phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.Danusertib, an aurora kinase inhibitor.Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.Update on aurora kinase inhibitors in gynecologic malignancies.Update on Aurora Kinase Targeted Therapeutics in Oncology.FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsKinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitorsA phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generatAurora kinase inhibitors as anticancer molecules.A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)Aurora A kinase (AURKA) in normal and pathological cell division.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Emerging drugs for high-grade osteosarcoma.Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).Aurora kinase inhibitors: progress towards the clinicENMD-2076 for hematological malignancies.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Multi-kinase inhibitors, AURKs and cancer.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatmentRandomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
P2860
Q26770583-A04273A2-BE9B-466F-8357-4FA73A4CD6CFQ26783412-52CD43C2-90F5-4C96-847F-75AFA436769AQ26801718-C5512837-4924-4D33-A6AC-3A8B1DC65FA9Q28475255-6AF1866A-581C-473E-95AA-A479DD5923D2Q28545195-69E0E93D-0E8B-423B-981A-C774E2A91147Q28654389-EC34A9E7-29FD-4E54-9B32-1C08C46D7ED5Q33406722-8CCB56DE-2205-4E83-9A80-B0A550255EAAQ33408947-E9607B23-CF4F-4EF3-B3D2-D77088EEAFF1Q34126899-6174FCAE-27A7-409A-8668-6B1238207FDDQ34293391-8F6E1F01-CF33-40B6-A841-897186BB380AQ34459957-15E4F7EA-38A6-4F3D-9EA7-FD60D909F98BQ34576017-6EB6B996-7361-46F6-8ABE-A679911F2488Q34941504-2BBDEC6F-1BC3-4AEA-97B5-5A12A13D2807Q35206634-A102EA03-DE53-45BC-80D2-3F39F7A1E64CQ35289072-9BAE19D2-9686-44A4-92AD-EC5C507D94F8Q35691904-457A8A48-8075-435E-8C63-0DE96E33AB1CQ35800825-165FEFD5-12E9-4610-9303-46624B879F92Q35850203-A839549A-18EC-4FFD-B4CA-B78C42F769C8Q36342432-D28DD6BF-0ECB-4E12-8C06-0595530013CCQ36373227-900CB7A4-0454-4615-9F4F-FA3D2512A140Q36715681-58E9ADE8-D449-414C-8E89-B07275F128A6Q37401839-C395AAFC-44F7-4714-9E91-B8CF944CE512Q37690579-45127289-1ABC-476C-8516-5C80DF9E6CFFQ37778400-ECEB198E-4A59-487E-9536-034BDF66F060Q37876882-7CC6B6AA-3C85-4187-8D59-854B2BDE7EDEQ37986455-25E02C30-AA91-48BE-82CB-B348EE328CF8Q37991379-ABD43582-1698-478F-909E-30ABB35CCFBFQ37994256-9276209E-247B-4110-849E-E332CF6041EFQ38099046-569BAB4F-0148-4F9E-B351-EEA1705FC6ACQ38223271-83E3565A-AC5B-4EB2-90E9-B0B9600F5272Q38525073-DE960FCF-7BDA-4D0E-9372-8A19367EF830Q38783162-AC294D16-1A74-46B4-9FF7-A2F984C558C7Q38796360-B76709D2-9AE1-48FD-9435-F671FBD39568Q38894287-9D2696F6-79FD-4D88-9C33-55E5DCEFE0E0Q39608458-8BB8CA52-0EB4-4B04-81CD-3E43F4E55264Q41463339-F1AD2D60-0EE6-48F8-9D07-1E3A30B05B7DQ42723757-5A1991E6-EC3A-4BAB-8F5B-E26DE5874F11Q43582917-29DC801D-9BD5-469C-A6DF-C5DD0669C844Q45087026-B8BBD57F-EFC8-42C5-894E-4FED11FDCD0AQ53277143-4C601A42-43A8-44C9-A9D9-DFE9B0382F8C
P2860
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@ast
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@en
type
label
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@ast
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@en
prefLabel
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@ast
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
A phase I dose-escalation stud ...... ts with advanced solid tumors.
@en
P2093
Bernard Laffranchi
Charu Aggarwal
David R Spigel
F Anthony Greco
Howard A Burris
Jonathan Cheng
Jurgen Moll
Mariangela Mariani
Maurizio Rocchetti
Roberta Ceruti
P2860
P304
P356
10.1158/1078-0432.CCR-09-1445
P407
P577
2009-10-13T00:00:00Z